4TEEN4 Pharmaceuticals
- Biotech or pharma, therapeutic R&D
We are developing a targeted therapy to inhibit DPP3. Procizumab will be a first-in-class antibody targeting the DPP3 pathway in cardiogenic shock.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}